Stay updated on KX2-361 Safety & PK in Refractory Malignancies Clinical Trial
Sign up to get notified when there's something new on the KX2-361 Safety & PK in Refractory Malignancies Clinical Trial page.

Latest updates to the KX2-361 Safety & PK in Refractory Malignancies Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page has undergone significant content removal, including the deletion of detailed study information regarding the drug KX2-361 and its clinical trial criteria, while a new version number has been added.SummaryDifference39%
- Check17 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check24 days agoNo Change Detected
- Check60 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check75 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check82 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check96 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
Stay in the know with updates to KX2-361 Safety & PK in Refractory Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KX2-361 Safety & PK in Refractory Malignancies Clinical Trial page.